SOPHiA GENETICS and Leading US Cancer Center Collaborate to Combine Cancer Analysis Technology for Liquid Biopsies
January 10 2023 - 8:03AM
Business Wire
SOPHiA GENETICS™ (Nasdaq: SOPH), a cloud-native software company
in the healthcare space, has entered an agreement with Memorial
Sloan Kettering Cancer Center (MSK) to offer clinicians and
researchers new solutions to expand their testing and analytical
capabilities. This includes incorporating proprietary Comprehensive
Genomic Panel (CGP) sequencing tests such as MSK-ACCESS®, which
will be commercialized by SOPHiA GENETICS as the first
comprehensive ctDNA liquid biopsy test powered by the SOPHiA DDMTM
Platform. By combining predictive algorithms, the power of the
global SOPHiA GENETICS network, and the clinical expertise of MSK
in cancer genomics, experts hope to expand access to precision
cancer analysis capabilities.
Together, SOPHiA GENETICS and MSK will collaborate to further
develop MSK-ACCESS®, ensuring the solution takes advantage of the
sophisticated analytics of the SOPHiA DDMTM platform. The improved
assay will be designed to align with the most recent guidelines and
clinical trial data reflecting major actionable biomarkers.
“We’ve already had great collaboration in our discussions with
MSK and we see opportunity for building new solutions together that
will drive access to important data,” said Jurgi Camblong,
Cofounder and CEO of SOPHiA GENETICS. “By raising the bar for more
effective collective intelligence, we can create a new gold
standard for cancer care.”
As part of this agreement, SOPHiA GENETICS intends to build a
new clinico-genomic, cloud-native analytics platform that furthers
the impact of MSK’s extensive precision oncology data. This
includes the use of advanced machine learning algorithms to analyze
extensive multimodal data points to gain new insights. The goal of
the new SOPHiA CarePathTM module, paired with MSK’s CGP sequencing
tests, is to help inform and improve cancer care globally.
“We’re pleased to be collaborating with SOPHiA GENETICS to bring
our advanced precision oncology tools to a more diverse, global
population of people with cancer,” said Kojo S. J.
Elenitoba-Johnson, MD, Chair of the Department of Pathology and Lab
Medicine at MSK. “We believe accelerating access to precision
medicine, both in research and in patient care settings, can
improve cancer care and yield a wealth of scientific data to
advance our mission of reducing the burden of cancer
worldwide.”
More information will be discussed at the SOPHiA GENETICS
presentation during the 41st annual JP Morgan Healthcare Conference
on Tuesday, January 10th, 2022.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated
to establishing the practice of data-driven medicine as the
standard of care and for life sciences research. It is the creator
of the SOPHiA DDM™ Platform, a cloud-native platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
a broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook, and Instagram. Where others
see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management’s beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230110005272/en/
Media: Don Granese Manager, Media & Communications
media@sophiagenetics.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2023 to Jun 2024